RESUMEN
The fortieth author's name was listed incorrectly. The correct presentation is A Keski-Rahkonen.
RESUMEN
Anorexia nervosa (AN) is a complex neuropsychiatric disorder presenting with dangerously low body weight, and a deep and persistent fear of gaining weight. To date, only one genome-wide significant locus associated with AN has been identified. We performed an exome-chip based genome-wide association studies (GWAS) in 2158 cases from nine populations of European origin and 15 485 ancestrally matched controls. Unlike previous studies, this GWAS also probed association in low-frequency and rare variants. Sixteen independent variants were taken forward for in silico and de novo replication (11 common and 5 rare). No findings reached genome-wide significance. Two notable common variants were identified: rs10791286, an intronic variant in OPCML (P=9.89 × 10-6), and rs7700147, an intergenic variant (P=2.93 × 10-5). No low-frequency variant associations were identified at genome-wide significance, although the study was well-powered to detect low-frequency variants with large effect sizes, suggesting that there may be no AN loci in this genomic search space with large effect sizes.
Asunto(s)
Anorexia Nerviosa/genética , Moléculas de Adhesión Celular/genética , Exoma/genética , Familia , Femenino , Proteínas Ligadas a GPI/genética , Predisposición Genética a la Enfermedad/genética , Variación Genética/genética , Estudio de Asociación del Genoma Completo , Genotipo , Humanos , Intrones/genética , Masculino , Fenotipo , Polimorfismo de Nucleótido Simple/genética , Población Blanca/genéticaRESUMEN
PURPOSE: Non-alcoholic fatty liver disease (NAFLD) is a complex disease, resulting from a variety of genetic and environmental factors. The aim of this case-control study was to evaluate the effect of selected genetic polymorphisms, nutrition aspects and their interaction on the risk of NAFLD. METHODS: The sample consisted of 134 patients with NAFLD and 217 controls. Disease was diagnosed by liver ultrasound and volunteers were clinically and nutritionally assessed. Food groups were extracted from a 172 food-item FFQ questionnaire. Three genetic polymorphisms were assessed: PNPLA3 rs738409, TM6SF2 rs58542926 and GCKR rs780094. RESULTS: We replicated the effect of previously reported risk factors for NAFLD, such as elevated liver enzymes, obesity and metabolic syndrome. Food groups rich in simple sugars, fat and especially saturated fat were positively associated with NAFLD risk, whereas food groups rich in polyunsaturated fatty acids were reversely associated with the possibility of developing the disease (p < 0.05). Only the PNPLA3 genetic variant was statistically significantly associated with the disease (padditive = 0.015). However, it was found that a one-portion increase in fish intake increased the risk of NAFLD in carriers of the risk allele of TM6SF2 rs58542926 polymorphism compared to non-carriers, after adjusting for age, gender, energy intake, pack-years, PAL, TM6SF2 genotype and fish consumption (ORdominant = 1.503, 95% CI 1.094-2.064). CONCLUSIONS: Fish intake exerts an additive effect on NAFLD risk for carriers of the TM6SF2 polymorphism. This novel finding provides further rationale on the need for personalized nutritional advice, based on the genetic background of NAFLD patients.
Asunto(s)
Proteínas de la Membrana/genética , Enfermedad del Hígado Graso no Alcohólico/genética , Polimorfismo de Nucleótido Simple/genética , Alimentos Marinos , Adulto , Estudios de Casos y Controles , Femenino , Humanos , Hígado/diagnóstico por imagen , Masculino , Persona de Mediana Edad , Evaluación Nutricional , Factores de Riesgo , Encuestas y Cuestionarios , UltrasonografíaRESUMEN
BACKGROUND: Clinical recommendations to limit gestational weight gain (GWG) imply high GWG is causally related to adverse outcomes in mother or offspring, but GWG is the sum of several inter-related complex phenotypes (maternal fat deposition and vascular expansion, placenta, amniotic fluid and fetal growth). Understanding the genetic contribution to GWG could help clarify the potential effect of its different components on maternal and offspring health. Here we explore the genetic contribution to total, early and late GWG. PARTICIPANTS AND METHODS: A genome-wide association study was used to identify maternal and fetal variants contributing to GWG in up to 10 543 mothers and 16 317 offspring of European origin, with replication in 10 660 mothers and 7561 offspring. Additional analyses determined the proportion of variability in GWG from maternal and fetal common genetic variants and the overlap of established genome-wide significant variants for phenotypes relevant to GWG (for example, maternal body mass index (BMI) and glucose, birth weight). RESULTS: Approximately 20% of the variability in GWG was tagged by common maternal genetic variants, and the fetal genome made a surprisingly minor contribution to explain variation in GWG. Variants near the pregnancy-specific beta-1 glycoprotein 5 (PSG5) gene reached genome-wide significance (P=1.71 × 10-8) for total GWG in the offspring genome, but did not replicate. Some established variants associated with increased BMI, fasting glucose and type 2 diabetes were associated with lower early, and higher later GWG. Maternal variants related to higher systolic blood pressure were related to lower late GWG. Established maternal and fetal birth weight variants were largely unrelated to GWG. CONCLUSIONS: We found a modest contribution of maternal common variants to GWG and some overlap of maternal BMI, glucose and type 2 diabetes variants with GWG. These findings suggest that associations between GWG and later offspring/maternal outcomes may be due to the relationship of maternal BMI and diabetes with GWG.
Asunto(s)
Feto/fisiología , Ganancia de Peso Gestacional/genética , Embarazo/genética , Femenino , Estudio de Asociación del Genoma Completo , Ganancia de Peso Gestacional/fisiología , Humanos , Embarazo/fisiología , Embarazo/estadística & datos numéricosRESUMEN
PURPOSE: Zinc (Zn) plays an essential role in many biological processes including immune response. Impaired Zn status promotes immune dysfunction, and it has been associated with enhanced chronic inflammation during aging. It has been suggested that the measurement of circulating Zn by itself could not reflect the real Zn status of an individual. It is therefore necessary to identify other determinants associated with plasma Zn to better understanding how physiopathological conditions during aging may affect the concentration of this metal. METHODS: We have investigated the association between Zn levels and some biomarkers in 1090 healthy elderly from five European countries to increase the accuracy in the assessment of the Zn status. Stepwise multivariate linear regression models were used to analyze the influence of factors such as age, dietary intake, inflammatory mediators, laboratory parameters and polymorphisms previously associated with Zn homeostasis. RESULTS: Plasma Zn decrement was most strongly predicted by age, while positive correlations were found with albumin, RANTES and Zn intake after adjustment for multiple confounders. HSP70 +1267 AA genotype was an independent factor associated with Zn plasma concentrations. Cu/Zn ratio was positively associated with markers of systemic inflammation and age and negatively associated with albumin serum levels. CONCLUSIONS: Our findings show the most important independent determinants of plasma Zn concentration and Cu/Zn ratio variability in elderly population and suggest that the decline with age of Zn circulating levels is more dependent on physiopathological changes occurring with aging rather than to its nutritional intake.
Asunto(s)
Envejecimiento , Biomarcadores/sangre , Cobre/sangre , Zinc/sangre , Anciano , Anciano de 80 o más Años , Quimiocina CCL5/genética , Quimiocina CCL5/metabolismo , Estudios de Cohortes , Cobre/administración & dosificación , Dieta , Dieta Mediterránea , Europa (Continente) , Femenino , Técnicas de Genotipaje , Homeostasis , Humanos , Inflamación/sangre , Inflamación/fisiopatología , Masculino , Estado Nutricional , Albúmina Sérica/metabolismo , Zinc/administración & dosificaciónRESUMEN
BACKGROUND AND AIMS: Lifestyle habits including dietary intake and physical activity are closely associated with multiple body processes including glucose metabolism and are known to affect human health. Recent genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with glucose levels. The hypothesis tested here is whether a healthy lifestyle assessed via a score is associated with glycaemic traits and whether there is an interaction between the lifestyle and known glucose-raising genetic variants in association with glycaemic traits. METHODS AND RESULTS: Participants of Greek descent from the THISEAS study were included in this analysis. We developed a glucose preventive score (GPS) including dietary and physical activity characteristics. We also modelled a weighted genetic risk score (wGRS), based on 20 known glucose-raising loci, in order to investigate the impact of lifestyle-gene interaction on glucose levels. The GPS was observed to be significantly associated with lower glucose concentrations (ß ± SE: -0.083 ± 0.021 mmol/L, P = 1.6 × 10(-04)) and the wGRS, as expected, with increased glucose levels (ß ± SE: 0.020 ± 0.007 mmol/L, P = 8.4 × 10(-3)). The association of the wGRS with glucose levels was attenuated after interaction with the GPS. A higher GPS indicated decreasing glucose levels in the presence of an increasing wGRS (ß interaction ± SE: -0.019 ± 0.007 mmol/L, P = 0.014). CONCLUSION: Our results indicate that lower glucose levels underlie a healthier lifestyle and also support an interaction between the wGRS for known glycaemic loci and GPS associated with lower glucose levels. These scores could be useful tools for monitoring glucose metabolism.
Asunto(s)
Glucemia/metabolismo , Dieta Saludable , Ejercicio Físico , Sitios Genéticos , Predisposición Genética a la Enfermedad/prevención & control , Adulto , Anciano , Índice de Masa Corporal , Estudios Transversales , Femenino , Grecia , Humanos , Insulina/sangre , Modelos Lineales , Masculino , Persona de Mediana Edad , Polimorfismo de Nucleótido Simple , Factores de RiesgoRESUMEN
Proinflammatory cytokines and heat shock proteins play relevant roles in the pathogenesis of inflammatory diseases. We investigated whether Hsp70 1267 A/G and TNF-α -308 G/A polymorphisms are associated with proinflammatory mediators, zinc status and laboratory parameters in 1,078 healthy elderly from ZincAge study. Hsp70 1267 A/G genotype and allele distribution were similar among various European countries, while a TNF-α genetic heterogeneity was observed between the Northern and the Southern European populations, with a major frequency of the -308 A variant in France, Germany and Poland. We used linear regression models to test additive, dominant or recessive associations of each SNP with proinflammatory mediators, laboratory parameters, metallothioneins and zinc status. Hsp70 1267 A/G SNP, but not TNF-α -308 G/A SNP, influences TNF-α and IL-6 plasma levels under additive, dominant and recessive models (for TNF-α only). An association between Hsp70 1267 A/G SNP and zinc plasma levels was observed in the dominant model. In particular, G allele carriers showed increased circulating pro-inflammatory cytokines and zinc. Moreover, both these SNPs affect creatinine levels suggesting a possible influence on renal function. In conclusion, Hsp70 1267 A/G SNP is associated with pro-inflammatory cytokine production in healthy elderly and might represent a possible determinant of individual susceptibility to inflammatory diseases.
Asunto(s)
Envejecimiento/metabolismo , Citocinas/sangre , Proteínas HSP70 de Choque Térmico/genética , Inflamación/sangre , Polimorfismo de Nucleótido Simple/genética , Factor de Necrosis Tumoral alfa/genética , Zinc/metabolismo , Anciano , Anciano de 80 o más Años , Envejecimiento/genética , Proteína C-Reactiva/metabolismo , Europa (Continente) , Femenino , Frecuencia de los Genes/genética , Genotipo , Homeostasis/fisiología , Humanos , Inflamación/genética , Masculino , Metalotioneína/metabolismo , Persona de Mediana EdadRESUMEN
BACKGROUND AND AIMS: IL-18 expression is up-regulated in atherosclerotic plaques, and higher levels are seen in obese and Type 2 Diabetic individuals. More recently, a possible role for IL-18 in glucose and energy homeostasis has been suggested. METHODS AND RESULTS: We investigated variation within the IL18 gene and its association with measures of obesity and the metabolic syndrome. Five IL18 tagging single nucleotide polymorphisms (rs1946519, rs2043055, rs549908, rs360729, rs3882891) were selected and genotyped in the Gene-Diet Attica Investigation on childhood obesity (GENDAI) (age range 10-14 yrs); in young European men in the second European Atherosclerosis Research offspring Study (EARSII), an offspring study (age range 18-28 yrs) and in a group of healthy women from the Greek Obese Women study (GrOW) (age range 18-74 yrs). Six common haplotypes were observed. In GrOW, Hap6 (Frequency-2.6%) was associated with higher insulin levels (p<0.0001), estimates of HOMA(-Insulin Resistance) (p<0.0001) and HOMA(-ß-cell) (p<0.0001) compared to the common haplotype Hap1 (Frequency-33.2%). In EARSII, rs2043055 was associated with peak and area under the curve triglycerides (p=0.001 and p=0.002, respectively) after an oral fat tolerance test in 'cases' but not 'controls'. None of the haplotypes were associated with measures of body fatness in any of the studies. CONCLUSION: Association of IL18 variation with insulin levels and estimates of insulin resistance were only observed in our adult study, suggesting that the effects of IL-18 are only associated with increasing age. Taken together with the association of IL18 variants with post-prandial measures, this provides support for IL-18 as a metabolic factor.
Asunto(s)
Resistencia a la Insulina/genética , Insulina/sangre , Interleucina-18/genética , Síndrome Metabólico/genética , Obesidad/genética , Polimorfismo de Nucleótido Simple , Adolescente , Adulto , Anciano , Niño , Europa (Continente) , Femenino , Frecuencia de los Genes , Estudios de Asociación Genética , Predisposición Genética a la Enfermedad , Grecia , Humanos , Masculino , Síndrome Metabólico/sangre , Persona de Mediana Edad , Obesidad/sangre , Periodo Posprandial , Triglicéridos/sangre , Adulto JovenRESUMEN
BACKGROUND AND AIMS: Studies have consistently demonstrated that variants in a number of candidate genes are significant determinants of lipid levels in adults. However, few studies have investigated the impact of these variants in children. Therefore, in the present investigation we examined the influence of ten common variants in the genes for lipoprotein lipase (LPL-S447X), cholesterol ester transfer protein (CETP-Taq1B) apolipoprotein (APO) E (epsilon2, epsilon3, epsilon4), APOA5 (-1131C>T and S19W), APOA4 (S347T) and APOC3 (-482C>T; 1100C>T and 3238G>C) on lipoprotein levels children from the Gene-Diet Attica Investigation on childhood obesity (GENDAI). METHODS AND RESULTS: The ten variants selected were genotyped in 882 Greek children, mean age: 11.2+/-0.7 years (418 females and 464 males). Genotypes were assessed using TaqMan technology. Significantly higher total cholesterol (TC) (p=0.0001) and low-density lipoprotein cholesterol (LDL-C) (p<0.0001) were observed in APOE epsilon4 carriers compared to epsilon3/epsilon3 homozygotes and epsilon2 carriers. The association of APOE genotype with TC and high-density lipoprotein cholesterol (HDL-C) ratio (p=0.0008) was further modulated by body mass index. Carriers of the CETP TaqIB B2 allele had significantly higher HDL-C (p<0.0001) and significantly lower TC: HDL-C ratio (p<0.0001) compared to B1/B1 individuals. No significant associations were observed between APOA4, APOA5 and APOC3 variants and serum lipids. CONCLUSION: This study demonstrates that these common variants are associated with lipid levels in this healthy paediatric cohort, suggesting that even in these young children there may be potential in predicting their lifelong exposure to an adverse lipid profile.
Asunto(s)
Apolipoproteínas E/genética , Proteínas de Transferencia de Ésteres de Colesterol/genética , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Colesterol/sangre , Hipercolesterolemia/genética , Lipoproteína Lipasa/genética , Apolipoproteína C-III/genética , Apolipoproteínas A/genética , Índice de Masa Corporal , Niño , Colesterol/genética , HDL-Colesterol/genética , LDL-Colesterol/genética , Estudios de Cohortes , Femenino , Estudios de Asociación Genética , Grecia , Heterocigoto , Homocigoto , Humanos , Hipercolesterolemia/sangre , Masculino , Polimorfismo de Nucleótido Simple , Estadística como AsuntoRESUMEN
BACKGROUND: Sleeve gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB) are the most frequent bariatric surgery procedures worldwide. In this prospective study, we examined the association of a genetic risk score (GRS) with loss of excess weight after bariatric surgery. METHODS: A total of forty-seven morbidly obese Greek patients who underwent SG (81%) or RYGB were recruited, followed up for 2 years and genotyped. Weight loss after surgery was reported as the percentage of excess weight that was lost (%EWL) at 12 and 24 months after surgery. A GRS was constructed based on previously BMI- and WHR-related single nucleotide polymorphisms (SNPs) that were found significantly correlated with weight loss after bariatric surgery in our population. The level of post-surgery %EWL after 12 and 24 months was estimated through two multiple linear regression models that considered the effects of relevant genetic risk variants. RESULTS: The first proposed model suggested that the predictor variables of GRS, age, and BMI had a significant effect on %EWL12m. GRS was significantly associated with %EWL12m, indicating a 4.618% decrease of %EWL12m per score unit. The second model indicated a positive correlation between %EWL24m and %EWL12m, suggesting that while post-surgery weight loss increased during the first 12 months, an increase was expected in the next 12 months as well. GRS was also significantly associated with %EWL24m, indicating approximately 3% decrease of %EWL24m per score unit. CONCLUSION: GRS can be used in the future together with other preoperative parameters in order to predict the outcome of bariatric surgery.
Asunto(s)
Cirugía Bariátrica , Derivación Gástrica , Obesidad Mórbida , Gastrectomía , Humanos , Obesidad Mórbida/cirugía , Estudios Prospectivos , Estudios Retrospectivos , Factores de Riesgo , Resultado del Tratamiento , Pérdida de PesoRESUMEN
A large body of experimental research indicates that oxidative stress contributes to the processes related to aging and age-related diseases. Trace elements, particularly zinc (Zn), are essential components of the endogenous enzymatic antioxidant defenses. The aim of this study was to determine the activity of three main antioxidant enzymes in plasma [i.e. superoxide dismutase (pSOD), catalase (CAT), glutathione peroxidase (GPx)] and of SOD in erythrocyte (eSOD) in a group of 1108 healthy elderly subjects from different European countries. The same enzymatic activities were evaluated in a subgroup of 108 subjects before and after Zn supplementation. We observed that eSOD activity increased with age, whereas plasma Zn decreased. Moreover, we found that women showed higher eSOD activity and lower plasma Zn compared to men. There were no age and gender-related differences in the activities of pSOD, CAT and GPx. After Zn supplementation, the activities of Zn-dependent enzymes (pSOD and eSOD), as well as plasma Zn concentration, were significantly higher than before supplementation. These results were not influenced by age, gender, plasma Zn variations (Delta Zn) and geographic area. These data suggest the potential beneficial effects of Zn supplementation on Zn-dependent antioxidant enzymes in healthy elderly subjects.
Asunto(s)
Envejecimiento/metabolismo , Oxidorreductasas/efectos de los fármacos , Oligoelementos/farmacología , Zinc/farmacología , Anciano , Anciano de 80 o más Años , Catalasa/efectos de los fármacos , Catalasa/metabolismo , Suplementos Dietéticos , Eritrocitos/enzimología , Femenino , Glutatión Peroxidasa/efectos de los fármacos , Glutatión Peroxidasa/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Estrés Oxidativo/efectos de los fármacos , Oxidorreductasas/metabolismo , Caracteres Sexuales , Superóxido Dismutasa/efectos de los fármacos , Superóxido Dismutasa/metabolismo , Oligoelementos/administración & dosificación , Zinc/administración & dosificación , Zinc/deficienciaRESUMEN
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD), which is caused by mutations in polycystins 1 (PC1) and 2 (PC2), is one of the most commonly inherited renal diseases, affecting ~1 : 1000 Caucasians. MATERIALS AND METHODS: We screened Greek ADPKD patients with the denaturing gradient gel electrophoresis (DGGE) assay and direct sequencing. RESULTS: We identified a patient homozygous for a nucleotide change c.1445T > G, resulting in a novel homozygous substitution of the non-polar hydrophobic phenylalanine to the polar hydrophilic cysteine in exon 6 at codon 482 (p.F482C) of the PKD2 gene and a de-novo PKD1 splice-site variant IVS21-2delAG. We did not find this PKD2 variant in a screen of 280 chromosomes of healthy subjects, supporting its pathogenicity. The proband's parents did not have the PKD1 mutation. Real-time PCR of the PKD2 transcript from a skin biopsy revealed 20-fold higher expression in the patient than in a healthy subject and was higher in the patient's peripheral blood mononuclear cells (PBMCs) than in those of her heterozygote daughter and a healthy subject. The greater gene expression was also supported by Western blotting. Inner medullar collecting duct (IMCD) cells transfected with the mutant PKD2 mouse gene presented a perinuclear and diffuse cytoplasmic localization compared with the wild type ER localization. Patch-clamping of PBMCs from the p.F482C homozygous and heterozygous subjects revealed lower polycystin-2 channel function than in controls. CONCLUSIONS: We report for the first time a patient with ADPKD who is heterozygous for a de novo PKD1 variant and homozygous for a novel PKD2 mutation.
Asunto(s)
Riñón Poliquístico Autosómico Dominante/genética , Proteínas/genética , Animales , Células Cultivadas , Análisis Mutacional de ADN , Electroforesis/métodos , Femenino , Homocigoto , Humanos , Masculino , Ratones , Mutación , Reacción en Cadena de la Polimerasa , Canales Catiónicos TRPPRESUMEN
UNLABELLED: INTRODUCTION--HYPOTHESIS: Since the genetic bases of bone mass regulation in males are still poorly understood and the role of calciotropic hormones on bone mineral metabolism is absolute, our hypothesis is based on the certainty that specific genetic polymorphism will contribute, at least, on bone mass values. Our objective was to examine the relative contribution of genetic variables to the regulation of bone values in a population of young healthy men, focusing on the BsmI polymorphism of vitamin D receptor (VDR) gene and the AluI polymorphism of calcitonin receptor (CTR) gene. METHODS: Areal bone mineral density (aBMD), bone mineral content (BMC) and geometrical areas at specific skeletal sites of the forearm, of 301 healthy Caucasian young men, aged 18-25, were assessed by single X-ray absorptiometry (Osteometer DTX-100). VDR and CTR alleles were determined by BsmI and AluI endonuclease restriction fragment analyses. Analysis of covariance was used as a statistical model. RESULTS: No significant differences in the forearm aBMD, BMC or in area values were observed between the VDR and CTR genotypes. Findings did not change after adjusting for demographic characteristics. CONCLUSIONS: The BsmI and AluI polymorphisms are not related to the forearm bone values either reflecting mass or geometrical variables in this male population.
Asunto(s)
Densidad Ósea/genética , Antebrazo , Polimorfismo Genético , Receptores de Calcitonina/genética , Receptores de Calcitriol/genética , Absorciometría de Fotón , Adolescente , Adulto , Estudios de Cohortes , Genotipo , Grecia , Humanos , Masculino , Adulto JovenRESUMEN
Several naturally occurring constituents have received considerable attention because of their potential antioxidant activity. Consuming a diet rich in natural antioxidants has been associated with prevention from and/or treatment of atherosclerosis. Bioactive components of food, which are of special interest, include the Vitamins E and C, polyphenols, carotenoids-mainly lycopene and beta-carotene, and coenzyme Q10, featured by antioxidant properties. Antioxidant therapy is supposed to be effective in the early stages of atherosclerosis by preventing LDL oxidation and the oxidative lesion of endothelium. This review focuses on the effect of dietary antioxidants pertained to LDL oxidation and to the vascular endothelial dysfunction. Now that the human genome has been completely sequenced, genetic factors involved in oxidation may open new horizons to identify persons at risk for cardiovascular disease, allowing effective dietary intervention strategies to recover normal homeostasis and to prevent diet-related implications. On this basis, current studies on the action of selected antioxidant nutraceuticals on the activity of transcription factors, such as final targets in the signal transduction cascade and gene regulation, may emerge into new treatment concepts.
Asunto(s)
Antioxidantes/farmacología , Aterosclerosis/prevención & control , Dieta , Regulación de la Expresión Génica , Animales , Antioxidantes/metabolismo , Aterosclerosis/tratamiento farmacológico , Modelos Animales de Enfermedad , Endotelio Vascular/metabolismo , Humanos , Lipoproteínas LDL/metabolismo , Modelos Biológicos , Estrés Oxidativo , Oxígeno/metabolismo , Transcripción Genética , Vitaminas/metabolismoRESUMEN
Familial hypercholesterolaemia is a genetic disorder characterised by high low-density lipoprotein (LDL) cholesterol concentrations, which frequently gives rise to premature coronary artery disease (CAD). The clinical expression of familial hypercholesterolaemia is highly variable even in patients carrying the same LDL receptor gene mutation. This variability may be due to environmental and other genetic factors. Apolipoprotein E (Apo-E) has been extensively studied for its effects on the phenotype of familial hypercholesterolaemia. In this study we examined the influence of Apo-E genotype on lipid parameters and the incidence of CAD in 93 Greek patients with familial hypercholesterolaemia. Apo-E E2, E3 and E4 allele frequencies were 0.06, 0.86 and 0.09 respectively. The levels of total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, apolipoproteins A and B and lipoprotein alpha did not differ significantly among carriers and non-carriers of the E4 allele. The prevalence of CAD and hypertension did not differ either. Our results suggest that the E4 allele is not associated with lipid levels or with the prevalence of CAD among familial hypercholesterolaemia patients of the Greek population.
Asunto(s)
Apolipoproteínas E/genética , Enfermedad de la Arteria Coronaria/genética , Hiperlipoproteinemia Tipo II/genética , Lípidos/sangre , Polimorfismo Genético , Adulto , Femenino , Humanos , Hiperlipoproteinemia Tipo II/sangre , MasculinoRESUMEN
We investigated the effect of intracellular glutathione (GSH) levels on Natural Killer-mediated apoptosis in cisplatin-resistant K562 cells. K562/B6 and K562/C9 are cisplatin-resistant K562 cells less susceptible to lysis by natural killer cells. Cisplatin-resistant K562 cells did not present the apoptotic pattern of DNA fragmentation as it was observed for their maternal counterparts. K562/B6 and K562/C9 cell lines produce 1.6- and 1.9-times more GSH than K562 cells. Treatment of both cell lines with D,L-buthionine-(S,R)-sulfoximine (BSO, a gamma-glutamyl cysteine synthetase inhibitor) decreased GSH levels and augmented cell death induced by NK cells via a necrotic rather than an apoptotic process. Proliferating cell nuclear antigen (PCNA) expression was elevated in cisplatin-resistant K562 subclones, and the reduction of GSH levels after treatment with BSO decreased the expression of PCNA. These results suggest that the GSH level affects the NK cell-mediated cell death of cisplatin-resistant K562 cells by inducing necrosis rather than apoptosis.
Asunto(s)
Apoptosis , Glutatión/metabolismo , Células Asesinas Naturales/fisiología , Necrosis , Antígeno Nuclear de Célula en Proliferación/metabolismo , Antineoplásicos/farmacología , Butionina Sulfoximina/farmacología , Separación Celular , Cisplatino/farmacología , Técnicas de Cocultivo , Pruebas Inmunológicas de Citotoxicidad , Fragmentación del ADN , Resistencia a Antineoplásicos , Inhibidores Enzimáticos/farmacología , Citometría de Flujo , Colorantes Fluorescentes/metabolismo , Humanos , Células K562RESUMEN
The use of the chromium-release assay to determine cytotoxicity of effector against target cells has various limitations mostly due to the inherent properties of the radioactive substance. We have developed an improved flow cytometric method that is able to measure cytotoxicity, based on two fluorescent dyes. Calcein-AM, a non-fluorescent substance which is intracellularly converted to the green fluorescent calcein by esterase activity in viable cells, is initially used to stain target cells. After incubating targets with effectors for 2 h, ethidium homodimer-1, a red DNA stain non-permeable to viable cells, is added. Dead target cells are distinguished by their double (green-red) staining. Data analysis is performed by gating the regions of living target, dead target and living effector cells, based on appropriate controls. Non-specific events are subtracted from the dead target region and the ratio of specific dead target events to total target events is expressed as percent cytotoxicity. The method is used to quantify natural killer (NK) and lymphokine-activated killer (LAK) activities against the human K562 and Daudi cell lines and the murine YAC-1 and L1210 cell lines respectively, as well as cell-mediated lympholysis (CML) exerted by tumor-infiltrating lymphocytes (TIL) against autologous and allogeneic human breast cancer tumor cells. The method is fast, reliable and correlates well with the standard 51Cr-release assay.
Asunto(s)
Pruebas Inmunológicas de Citotoxicidad , Citometría de Flujo/métodos , Animales , Relación Dosis-Respuesta Inmunológica , Fluoresceínas , Colorantes Fluorescentes , Humanos , Inmunidad Celular , Técnicas In Vitro , Células Asesinas Activadas por Linfocinas/inmunología , Células Asesinas Naturales/inmunología , Ratones , Ratones Endogámicos BALB CRESUMEN
The development of resistance to cisplatin (CDDP) occurs both in vitro and in vivo. We cultured K562 cells with continuous exposure to gradually increasing doses of CDDP and produced CDDP resistant K562 sublines. CDDP-resistant sublines were found to be cross-sensitive to Mit-C and cross-resistant to DXR and cyclophosphamide. These sublines were tested for their susceptibility to NK-mediated lysis using NK cells isolated from 10 healthy donors and 12 patients with breast cancer. K562/B6 and K562/C9 CDDP-resistant sublines were more resistant (22 +/- 5% and 19 +/- 3% lysis, respectively for Ca patients, and 34 +/- 6 and 31 +/- 5% for healthy donors) than the maternal K562 cells (36 +/- 3% for Ca patients and 55 +/- 5% for healthy individuals). The correlation of cisplatin resistance, with a diminished susceptibility by NK lysis, should permit the selection of patients suitable for cisplatin-based chemotherapy.
Asunto(s)
Antineoplásicos/farmacología , Cisplatino/farmacología , Células Asesinas Naturales/inmunología , Leucemia Mielógena Crónica BCR-ABL Positiva/terapia , Adulto , Anciano , Neoplasias de la Mama/inmunología , Citotoxicidad Inmunológica , Resistencia a Antineoplásicos , Humanos , Inmunoterapia Adoptiva , Células Asesinas Activadas por Linfocinas/inmunología , Leucemia Mielógena Crónica BCR-ABL Positiva/tratamiento farmacológico , Leucemia Mielógena Crónica BCR-ABL Positiva/patología , Persona de Mediana Edad , Células Tumorales CultivadasRESUMEN
The expansion of myeloma cells is regulated by cytokines, among which IL-6 is a major growth factor. It has been recently suggested that serum transforming growth factor beta 1 (TGF beta 1), a cytokine found in large amounts in alpha-granules of platelets, might play a role in multiple myeloma (MM). It was the purpose of this study to determine serum TGF beta 1 levels in MM patients and to seek a correlation with disease parameters. Measurements were done by ELISA. We studied 35 MM patients (19 stage II, 16 stage III, 20 IgG, 8 IgA and 6 BJ, 1 IgD) in different phases of the disease, 27 healthy individuals and 17 thrombocytopenic patients with other haematological diseases (three MDS, three congenital thrombocytopenia, 11 ITP). Overall samples from MM patients were included: 10 at diagnosis, 18 in remission and 32 in relapse. In normal controls TGF beta 1 serum levels ranged from 1 to 33 ng/ml (median 16.5 ng/ml). In both thrombocytopenic controls with other diseases and thrombocytopenic MM patients (seven samples), TGF beta 1 serum levels were very low (median 3.2 and 4.5 ng/ml respectively). In MM patients with PLT > 100 x 10(9)/L (53 samples), TGF beta 1 serum levels were in the normal range in patients without immunoparesis (1 to 27 ng/ml, median 16.6 ng/ml), whereas they were higher in patients with immunoparesis (polyclonal immunoglobulins (Igs) below lower normal reference values) ranging from 10.2 to 45 ng/ml (median 26.8 ng/ml) (P < 0.01). Serum TGF beta 1 levels fluctuated in the same patient at different times but not according to relapse or remission. Correlation was found only between serum TGF beta 1 levels and immunoparesis and not between serum TGF beta 1 levels and disease stage or Ig subtype nor with prognostic factors for MM (serum CRP, beta 2M or IL-6). This finding suggests that the remaining normal plasma cells are sensitive to the inhibitory action of TGF beta 1 on Ig production. In conclusion TGF beta 1 serum levels are very low in thrombocytopenic patients confirming that platelets are the major source of this cytokine. Furthermore, a strong correlation was found between TGF beta 1 serum levels and immunoparesis in MM patients.
Asunto(s)
Mieloma Múltiple/inmunología , Factor de Crecimiento Transformador beta/sangre , Adulto , Anciano , Anciano de 80 o más Años , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Inmunoglobulinas/sangre , Masculino , Persona de Mediana Edad , Mieloma Múltiple/sangre , Recuento de Plaquetas , PronósticoRESUMEN
Epirubicin is an anthracyclinic antibiotic that has been increasingly used in the treatment of a variety of malignancies. A hybridoma producing monoclonal antibody (MAb) against the drug was obtained by cell fusion. The MAb is of the IgM isotype and has an affinity constant of 1.4 x 10(-7) M. Inhibition analysis showed that the antibody recognizes an epitope related to the C 4'-hydroxyl group in the amino sugar moiety, distinguishing epirubicin from the closely related doxorubicin. Since the precise mechanism of anthracycline action as well as its immunomodulating effects are still under scrutiny, powerful tools for their study are clearly needed. Moreover, this MAb can be useful in monitoring the levels of epirubicin in treated patients, as well as for the construction of bispecific antibodies in tumor-targeting immunotherapy.